BioCryst Pharmaceuticals, Inc.

NasdaqGS:BCRX Stock Report

Market Cap: US$1.5b

BioCryst Pharmaceuticals Valuation

Is BCRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BCRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$69.3
Fair Value
89.9% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: BCRX ($7.03) is trading below our estimate of fair value ($69.3)

Significantly Below Fair Value: BCRX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BCRX?

Key metric: As BCRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BCRX. This is calculated by dividing BCRX's market cap by their current revenue.
What is BCRX's PS Ratio?
PS Ratio2.5x
SalesUS$599.82m
Market CapUS$1.48b

Price to Sales Ratio vs Peers

How does BCRX's PS Ratio compare to its peers?

The above table shows the PS ratio for BCRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.9x
IMCR Immunocore Holdings
4.2x17.08%US$1.6b
AUPH Aurinia Pharmaceuticals
6.9x12.45%US$1.9b
TWST Twist Bioscience
5.1x14.09%US$1.8b
SNDX Syndax Pharmaceuticals
11.5x40.43%US$1.3b
BCRX BioCryst Pharmaceuticals
2.5x13.62%US$1.5b

Price-To-Sales vs Peers: BCRX is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (6.9x).

Price to Sales Ratio vs Industry

How does BCRX's PS Ratio compare vs other companies in the US Biotechs Industry?

152 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.11.2x21.0%
BCRX BioCryst Pharmaceuticals
 2.5x13.62%US$1.48b
AMGN Amgen
4.7x1.84%US$172.24b
REGN Regeneron Pharmaceuticals
4.7x6.82%US$66.09b
BCRX 2.5xIndustry Avg. 11.2xNo. of Companies152PS020406080100+
152 CompaniesEstimated GrowthMarket Cap
Industry Avg.11.2x23.8%
BCRX BioCryst Pharmaceuticals
 2.5x55.49%US$1.48b
No more companies

Price-To-Sales vs Industry: BCRX is good value based on its Price-To-Sales Ratio (2.5x) compared to the US Biotechs industry average (11.2x).

Price to Sales Ratio vs Fair Ratio

What is BCRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BCRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.5x
Fair PS Ratio4.6x

Price-To-Sales vs Fair Ratio: BCRX is good value based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BCRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.03
US$19.73
+180.62%
34.52%US$30.00US$9.00n/a11
Oct ’26US$7.37
US$16.36
+122.03%
35.75%US$30.00US$8.00n/a11
Sep ’26US$8.31
US$16.73
+101.29%
32.45%US$30.00US$11.00n/a11
Aug ’26US$7.95
US$16.64
+109.26%
31.94%US$30.00US$11.00n/a11
Jul ’26US$9.00
US$16.64
+84.85%
31.94%US$30.00US$11.00n/a11
Jun ’26US$10.75
US$16.58
+54.26%
30.89%US$30.00US$11.00n/a12
May ’26US$8.71
US$15.17
+74.13%
38.43%US$30.00US$8.00n/a12
Apr ’26US$7.25
US$14.73
+103.13%
40.02%US$30.00US$8.00n/a11
Mar ’26US$8.61
US$15.42
+79.06%
39.50%US$30.00US$8.00n/a12
Feb ’26US$7.90
US$15.27
+93.33%
42.44%US$30.00US$8.00n/a11
Jan ’26US$7.52
US$14.82
+97.05%
43.24%US$30.00US$8.00n/a11
Dec ’25US$7.50
US$14.64
+95.15%
43.34%US$30.00US$8.00n/a11
Nov ’25US$8.43
US$14.45
+71.47%
43.99%US$30.00US$7.00US$7.3211
Oct ’25US$7.38
US$14.45
+95.86%
43.99%US$30.00US$7.00US$7.3711
Sep ’25US$8.69
US$14.45
+66.34%
43.99%US$30.00US$7.00US$8.3111
Aug ’25US$7.11
US$14.00
+96.91%
46.69%US$30.00US$6.00US$7.9511
Jul ’25US$6.67
US$14.00
+109.90%
46.69%US$30.00US$6.00US$9.0011
Jun ’25US$6.46
US$14.00
+116.72%
46.69%US$30.00US$6.00US$10.7511
May ’25US$4.57
US$13.82
+202.37%
46.68%US$30.00US$6.00US$8.7111
Apr ’25US$5.05
US$13.82
+173.63%
46.68%US$30.00US$6.00US$7.2511
Mar ’25US$5.62
US$13.82
+145.88%
46.68%US$30.00US$6.00US$8.6111
Feb ’25US$5.28
US$13.82
+161.71%
46.68%US$30.00US$6.00US$7.9011
Jan ’25US$5.99
US$14.09
+135.24%
46.24%US$30.00US$6.00US$7.5211
Dec ’24US$6.15
US$14.09
+129.12%
46.24%US$30.00US$6.00US$7.5011
Nov ’24US$5.73
US$15.20
+165.27%
46.22%US$30.00US$8.00US$8.4310
US$19.73
Fair Value
64.4% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/07 12:24
End of Day Share Price 2025/11/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioCryst Pharmaceuticals, Inc. is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Tazeen AhmadBofA Global Research
Dae Gon HaBTIG